Continue reading here:
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
Category Archives: Global News Feed
Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos…
Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board
See the original post:
Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board
Mountain Valley MD Successfully Completes Pre-Clinical Pharmacokinetic Study For Soluvec™1%
See the original post here:
Mountain Valley MD Successfully Completes Pre-Clinical Pharmacokinetic Study For Soluvec™1%
Sanofi: Information concerning the total number of voting rights and shares – May 2022
Read the original here:
Sanofi: Information concerning the total number of voting rights and shares – May 2022
Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application
Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics
Acerus Announces Voting Results for the 2022 Annual Meeting
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022
Vaccitech to Present at the H.C. Wainwright Global Investment Conference
G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal
Biomea Fusion to Attend H.C. Wainwright Global Investment Conference
The rest is here:
Biomea Fusion to Attend H.C. Wainwright Global Investment Conference
Growcentia, a leading provider of scientifically driven biological solutions for agriculture and horticulture, celebrates grand opening of new…
Results of the votes of the Combined Shareholders’ Meeting of May 19, 2022
See the rest here:
Results of the votes of the Combined Shareholders’ Meeting of May 19, 2022
Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.
Go here to read the rest:
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.